Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 227 participants.
Also called NCT06122779
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 227 participants
- Sponsor
- Registry
-
NCT06122779 -
2023-505919-21
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Canada, China, Israel, Italy, Japan, Poland, South Korea, Spain, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06122779. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-07 (actual); primary completion 2026-12-14 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
- Acronym
- AURORA-HFpEF
- Condition
- Heart Failure
- Intervention (Drug)
- BMS-986435
- Intervention (Other)
- Placebo
- Lead sponsor
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct06122779- Content hash
76b7a972121f6df976e66708643f65882a2bec76db1376332bfccbb708b04c73